Abstract | OBJECTIVE: SAMPLE: 1,440 samples of PBMCs from 6 healthy research horses. PROCEDURES: From heparinized whole blood samples, PBMC cultures were obtained. An initial dose-response trial on 48 PBMC samples from 2 horses (24 samples each) was used to determine concentrations of IFN-γ and LPS for use as low- and high-level stimulation concentrations. Seventy-two PBMC samples from 6 horses were assigned equally to 1 of 4 PARP1 inhibition categories: no PARP1 inhibitor (PARP1 inhibition control); 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carbozamide dihydrochloride ( ABT888);4-(3-(1-(cyclopropanecarbonyl) piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one ( AZD2281); or N-(6-oxo-5,6-dihydrophenanthridin-2-yl) - N,N-dimethylacetamide hydrochloride ( PJ34). Samples of PBMCs from each horse and each PARP1 inhibition category were then assigned to 1 of 3 levels of IFN-γ and LPS stimulation: none (control), low stimulation, or high stimulation. After a 24-hour incubation period, a TNF-α ELISA was used to measure TNF-α concentration in the supernatant. Results were compared across treatments and for each horse. Data were analyzed with repeated-measures ANOVA. RESULTS: Median TNF-α concentration was significantly lower for PJ34-treated, high-level stimulated PBMCs than for PARP1 inhibition control, high-level stimulated PBMCs; however, no other meaningful differences in TNF-α concentration were detected among the inhibition and stimulation combinations. CONCLUSIONS AND CLINICAL RELEVANCE: Findings suggested that PJ34 PARP1 inhibition may reduce TNF-α production in horses, a potential benefit in reducing inflammation and endotoxin-induced damage in horses.
|
Authors | Cristina Cacciolatti, Mirella L Meyer-Ficca, Louise L Southwood, Ralph G Meyer, Luigi Bertolotti, Laura Zarucco |
Journal | American journal of veterinary research
(Am J Vet Res)
Vol. 80
Issue 7
Pg. 663-669
(Jul 2019)
ISSN: 1943-5681 [Electronic] United States |
PMID | 31246122
(Publication Type: Journal Article)
|
Chemical References |
- Lipopolysaccharides
- Poly(ADP-ribose) Polymerase Inhibitors
- Tumor Necrosis Factor-alpha
- Interferon-gamma
- Poly(ADP-ribose) Polymerases
|
Topics |
- Animals
- Disease Models, Animal
- Horse Diseases
(physiopathology)
- Horses
(blood)
- In Vitro Techniques
- Inflammation
(physiopathology)
- Interferon-gamma
(metabolism)
- Leukocytes, Mononuclear
(drug effects, enzymology)
- Lipopolysaccharides
(pharmacology)
- Poly(ADP-ribose) Polymerase Inhibitors
(pharmacology)
- Poly(ADP-ribose) Polymerases
(metabolism)
- Tumor Necrosis Factor-alpha
(metabolism)
|